Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology

Authors


  • Conflict of interest
    Dr Braathen has received speakers’ honoraria from Galderma and received financial support from Galderma and PhotoCure for performing clinical trials. He has consulted for PhotoCure. Dr Morton has received financial speakers’ honoraria from Galderma and is a member of Leo Pharma and Basilea advisory boards. He has received travel scholarships from 3M, PhotoCure and Phototherapeutics Ltd. Dr Basset-Seguin does consultant work for Galderma, 3M, Meda, PhotoCure,Vichy, Roche, Novartis and P Fabre. She has received financial support from Photocure, 3M, Meda and Genentech for performing clinical trials. Dr Bissonnette has received speakers’ honoraria from Galderma and Leo Pharma. He has received financial support from PhotoCure, Graceway, Galderma, Leo Pharma and DUSA Pharmaceuticals for performing clinical trials. Dr Gerritsen has received speakers’ honoraria from Galderma, 3M and Medac and joined Galderma advisory board. She has received financial support from PhotoCure, Galderma and 3M, for performing clinical trials. Dr Gilaberte has received speakers’ honoraria from Galderma, Astellas and Abbott. She has received financial support from Pfizer for performing clinical studies. Dr Calzavara-Pinton has received speakers’ honoraria from Galderma, Pfizer, Schering-Plough, La Roche Posay, Pierre Fabre, Leo and Difa-Cooper. He has received financial support from PhotoCure ASA, Pfizer, Difa-Cooper, Serono and Schering Plough for performing clinical trials. Dr Sidoroff has received financial speakers’ honoraria from Galderma. Dr Wulf has received speakers’ honoraria from and is a consultant for Galderma and PhotoCure. Dr Szeimies has served as a consultant for, and has received speakers’ honoraria from Galderma. He has received financial support from Almirall, Energist, Intendis, 3M, PhotoCure, photonamic, Waldmann Medizintechnik and Wavelight AG for performing clinical trials.

  • Funding sources
    The work of the IPDT was supported by an educational grant from Galderma International, Paris, France.

*L.R. Braathen. E-mail: lasse.r.braathen@bluewin.ch

Abstract

Field cancerization is a term that describes the presence of genetic abnormalities in a tissue chronically exposed to a carcinogen. These abnormalities are responsible for the presence of multilocular clinical and sub-clinical cancerous lesions that explains the increased risks of multiple cancers in this area. With respect to the skin, this term is used to define the presence of multiple non-melanoma skin cancer, its precursors, actinic keratoses and dysplastic keratinocytes in sun exposed areas. The multiplicity of the lesions and the extent of the area influence the treatment decision. Providing at least equivalent efficacy and tolerability, field directed therapies are therefore often more worthwhile than lesion targeted approaches. Photodynamic therapy (PDT) with its selective sensitization and destruction of diseased tissue is one ideal form of therapy for this indication. In the following paper the use of PDT for the treatment of field cancerized skin is reviewed and recommendations are given for its use.

Ancillary